Core Viewpoint - The company reported a decline in revenue and net profit for the first half of 2025, but maintained strong cash flow and profitability metrics, indicating resilience despite market challenges [2][5]. Financial Performance - In the first half of 2025, the company achieved revenue of 1.134 billion yuan, a year-on-year decrease of 24.15% - Net profit was 389 million yuan, down 29.46% compared to the previous year - Operating cash flow was 538 million yuan, exceeding net profit by 149 million yuan, reflecting high-quality cash flow [2]. Business Segment Performance - **Nephrology Sector**: Sales revenue from nephrology products reached 784.97 million yuan, accounting for 69.20% of total revenue. The KHA series products generated 79.98 million yuan in sales, up 27.34% year-on-year, while pHA series sales increased by 374.22% to 11.75 million yuan [3]. - **Hepatology Sector**: Revenue from hepatology products was 131.53 million yuan, representing 11.59% of total revenue [3]. - **Critical Care Sector**: Sales in this area totaled 142.31 million yuan, making up 12.54% of total revenue, with a notable 36.15% increase in sales from the CA series [3]. - **Blood Purification Equipment**: Revenue was 19.34 million yuan, accounting for 1.71% of total revenue [3]. - **International Business**: Overseas revenue reached 34.44 million yuan, representing 3.04% of total revenue, with products used in over 2,000 hospitals across 98 countries [3]. Research and Development - The company invested 97 million yuan in R&D, which is 8.59% of revenue, and obtained 15 new patents during the reporting period [4]. - Two products received CE certification under the latest EU MDR regulations, and a new product for medical waste disposal was registered [4]. Dividend and Social Responsibility - The company distributed a cash dividend of 620 million yuan (including tax), with a payout ratio exceeding 75% [4]. - It contributed 19.17 million yuan in cash and materials for public welfare projects during the reporting period [4]. Future Outlook - The company anticipates a decline in revenue due to price adjustments and high base effects from the previous year, but plans to deepen its focus on blood purification and expand both domestic and international markets [5]. - The company is exploring new business areas related to metabolic cardiovascular diseases and has initiated a clinical study on plasma adsorption in stroke patients [5]. - The company aims to maintain a stable and sustainable dividend policy, having distributed a total of 4.07 billion yuan since its IPO [5].

Group 1 - The core viewpoint of the news highlights the performance and valuation of Jianfan Biological, noting its current stock price, market capitalization, and comparison with industry averages [1][2]. - Jianfan Biological's stock closed at 23.45 yuan, with a rolling PE ratio of 25.86 times, and a total market value of 18.727 billion yuan [1]. - The average PE ratio for the medical device industry is 56.58 times, with a median of 39.97 times, positioning Jianfan Biological at the 53rd rank within the industry [1][3]. Group 2 - Jianfan Biological specializes in the research, production, and sales of biomaterials and high-tech medical devices, with key products including various blood purification devices and solutions [2]. - The company has received multiple accolades, including recognition as a key high-tech enterprise under the National Torch Program and has established several research platforms [2]. - In the latest quarterly report for Q1 2025, Jianfan Biological reported revenue of 548 million yuan, a year-on-year decrease of 26.40%, and a net profit of 189 million yuan, down 33.71%, with a gross profit margin of 80.74% [2].

Group 1 - The core business of the company is the research, production, and sales of biomaterials and high-tech medical devices, with major products including various blood purification devices and solutions [2] - As of the first quarter of 2025, the company reported a revenue of 548 million yuan, a year-on-year decrease of 26.40%, and a net profit of 189 million yuan, a year-on-year decrease of 33.71%, with a gross profit margin of 80.74% [2] - The company has received multiple national and provincial recognitions, including being designated as a key high-tech enterprise under the National Torch Program and a national technology innovation demonstration enterprise [2] Group 2 - The company's current rolling price-to-earnings (PE) ratio is 24.60, while the average PE ratio for the medical device industry is 51.83, and the industry median is 37.23 [1][3] - The total market capitalization of the company is 17.817 billion yuan, ranking it 52nd in the industry based on PE ratio [1][3] - As of the first quarter of 2025, there are 12 institutions holding shares in the company, with a total holding of approximately 62.5493 million shares valued at 1.633 billion yuan [1]

Company Overview - Jianfan Biological Technology Group Co., Ltd. specializes in the research, production, and sales of biomaterials and high-tech medical devices [2] - The main products include various blood perfusion devices, dialysis solutions, disinfectants, and blood purification equipment [2] - The company has received multiple accolades, including being recognized as a key high-tech enterprise under the National Torch Program and a national champion in manufacturing [2] Financial Performance - As of the first quarter of 2025, the company reported revenue of 548 million yuan, a year-on-year decrease of 26.40% [2] - The net profit for the same period was 189 million yuan, down 33.71% year-on-year, with a gross profit margin of 80.74% [2] Market Position - The company's stock closed at 23.19 yuan, with a PE ratio of 25.57, marking a new low in 55 days [1] - The average PE ratio in the medical device industry is 51.05, with a median of 36.62, placing Jianfan Biological at the 56th position in the industry ranking [1][3] - The total market capitalization of the company is 18.52 billion yuan [1] Institutional Holdings - As of the first quarter of 2025, 12 institutions hold shares in Jianfan Biological, including 10 funds, with a total holding of approximately 62.55 million shares valued at 1.633 billion yuan [1]

Company Overview - Jianfan Biological Technology Group Co., Ltd. specializes in the research, production, and sales of biomaterials and high-tech medical devices [2] - The main products include various blood perfusion devices, dialysis solutions, disinfectants, and blood purification equipment [2] - The company has received multiple accolades, including being recognized as a key high-tech enterprise under the National Torch Program and a national champion in manufacturing [2] Financial Performance - As of Q1 2025, the company reported revenue of 548 million yuan, a year-on-year decrease of 26.40% [2] - The net profit for the same period was 189 million yuan, down 33.71% year-on-year [2] - The gross profit margin stands at 80.74% [2] Market Position - The company's current price-to-earnings (PE) ratio is 23.84, compared to the industry average of 49.46 and the industry median of 36.16 [1][3] - Jianfan Biological ranks 53rd in terms of PE ratio within the medical device industry [1] - The total market capitalization of the company is 17.266 billion yuan [1]

Company Overview - Jianfan Biological Technology Group Co., Ltd. specializes in the research, production, and sales of biomaterials and high-tech medical devices [2] - The main products include various blood perfusion devices, dialysis solutions, disinfectants, and blood purification equipment [2] - The company has received multiple accolades, including being recognized as a key high-tech enterprise under the National Torch Program and a national technology innovation demonstration enterprise [2] Financial Performance - As of Q1 2025, the company reported revenue of 548 million yuan, a year-on-year decrease of 26.40% [2] - The net profit for the same period was 189 million yuan, down 33.71% year-on-year, with a gross profit margin of 80.74% [2] Market Position - The company's stock closed at 21.69 yuan, with a rolling price-to-earnings (PE) ratio of 23.92 times, compared to the industry average of 48.90 times and the median of 36.41 times [1][3] - Jianfan Biological ranks 53rd in terms of PE ratio within the medical device industry [1] Institutional Holdings - As of Q1 2025, 12 institutions held shares in Jianfan Biological, including 10 funds, with a total holding of approximately 62.55 million shares valued at 1.633 billion yuan [1]

4月15日，健帆生物今日收盘24.39元，下跌1.26%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到24.21倍，总市值194.78亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均46.44倍，行业中值30.39倍，健帆生物排 名第59位。 截至2024年三季报，共有415家机构持仓健帆生物，其中基金415家，合计持股数10103.07万股，持股市 值29.64亿元。 健帆生物科技集团股份有限公司主要从事生物材料和高科技医疗器械的研发、生产及销售。主要产品有 血液灌流器、血液净化设备、血液透析粉液产品。公司先后获评为国家火炬计划重点高新技术企业、国 家制造业单项冠军示范企业、国家技术创新示范企业、国家知识产权示范企业。荣获国家科技进步二等 奖、广东省科学技术进步一等奖。 最新一期业绩显示，2024年三季报，公司实现营业收入21.96亿元，同比47.76%；净利润7.92亿元，同 比86.86%，销售毛利率81.31%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)59健帆生物24.2144.626.14194.78亿行业平均 46.4449.384.75102.60亿 ...

证券代码：300529 证券简称：健帆生物 公告编号：2025-010 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于不向下修正健帆转债转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 （二）可转债上市情况 经深交所同意，公司 100,000.00 万元可转换公司债券于 2021 年 7 月 21 日起 在深交所挂牌交易，债券简称"健帆转债"，债券代码"123117"。 1 （三）可转债转股期限 根据《深圳证券交易所创业板股票上市规则》等相关规定和《健帆生物科技 集团股份有限公司创业板向不特定对象发行可转换公司债券募集说明书》（以下 简称"《募集说明书》"）的有关约定，本次可转换公司债券转股期限自发行结 束之日（2021 年 6 月 29 日）满六个月后的第一个交易日起至可转换公司债券到 期之日止，即 2021 年 12 月 29 日至 2027 年 6 月 22 日。 （四）可转债转股价格调整情况 特别提示： 2025 年 2 月 25 日，健帆生物科技集团股份有限公司（以下简称"公司"） 召开第五届董事会第二十 ...

| 证券代码：300529 | 证券简称：健帆生物 | 公告编号：2025-009 | | --- | --- | --- | | 债券代码：123117 | 债券简称：健帆转债 | | 健帆生物科技集团股份有限公司 第五届董事会第二十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 健帆生物科技集团股份有限公司（以下简称"公司"）第五届董事会第二十 六次会议于 2025 年 2 月 25 日在公司会议室以现场会议及通讯表决的方式召开， 本次会议应出席董事 9 人，实际出席董事 9 人，符合《公司法》和《公司章程》 的有关规定。本次会议通知提前以电子邮件及电话通知等方式向全体董事送达。 公司董事长董凡先生召集和主持了本次会议，公司部分监事和高级管理人员列席 了会议。本次董事会的召开符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事认真讨论，审议并表决通过了以下议案： 1、审议通过了《关于不向下修正健帆转债转股价格的议案》 公司董事董凡、唐先敏、廖雪云为"健帆转债"持有人，董事雷雯系董凡之 配偶， ...